

PATENT/Docket No. PC22004B
Appl. No. 10/761,636
Filing Date: January 21, 2004
Reply to Office action of July 1, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

CLAIMS

1. (Currently amended) A veterinary formulation ~~comprising~~ suitable for topical application or spot-on application for administration to companion animals comprising ~~a 13-monosaccharide 5-oxime-avermectin~~ selamectin at around 1% to 16% w/v, and praziquantel at around 0.5-10%w/v, in a veterinarily acceptable carrier, diluent or adjuvant.
2. (Canceled)
3. (Original) The formulation according to claim 1 wherein the praziquantel is present at around 6% w/v.
4. (Original) The formulation according to claim 1 which further comprises a di(C₂₋₄ glycol) mono(C₁₋₄ alkyl) ether and an optional skin-acceptable solvent.
5. (Canceled)
6. (Currently amended) The formulation according to claim 1 wherein ~~the 13-monosaccharide 5-oxime-avermectin~~ said selamectin is provided at around 6-12mg/kg (with respect to the host animal) and praziquantel is provided at up to 18mg/kg (with respect to the host animal).
7. (Currently amended) The formulation according to claim 1 wherein ~~the 13-monosaccharide 5-oxime-avermectin~~ said selamectin is present at about 6% to about 12% w/v.
8. (original) The formulation according to claim 1 wherein the praziquantel is present in the formulation at about 3% to about 9% w/v.
9. (Canceled) The formulation according to claim 1 wherein the praziquantel is present in the formulation at about 6% w/v.

FORM AMEND
Rev. 5/27/03

PATENT/Docket No. PC22004B
Appl. No. 10/761,636
Filing Date: January 21, 2004
Reply to Office action of July 1, 2005

10. (Original) The formulation according to claim 1 wherein a di(C₂₋₄ glycol) mono(C₁₋₄ alkyl) ether is present, said ether being diethylene glycol monomethyl ether (DEGMME) or dipropylene glycol monomethyl ether (DPGMME).

11. (Original) The formulation according to claim 1 wherein a skin-acceptable solvent is present, said solvent being ethanol or isopropanol.

12. (Original) A formulation according to claim 1 which consists of:

- (a) selamectin, at a level of 1% to 16% w/v;
 - (b) DEGMME or DPGMME at 1 to 16% w/v, and at a w/v or v/v ratio of active compound to DEGMME/DPGMME of about 1:1;
 - (c) praziquantel at 0.5 to 10% w/v;
 - (d) isopropanol to volume (100%);
- and, optionally (e) BHT (at less than 0.1% w/v).

13. (Currently amended) A method of treatment and prophylaxis of parasitic infestation of flea, heartworm and tapeworm in a mammal which comprises administering a topical application or spot-on application to said mammal an amount of ~~a 13-monosaccharide 5-oxime avermectin, selected from the group consisting of~~ selamectin, and an amount of praziquantel, each amount being effective to treat or provide prophylaxis to the mammal.

14. (Currently amended) The method according to claim 13 wherein the ~~13-monosaccharide 5-oxime avermectin, selected from the group consisting of~~ selamectin and praziquantel are administered separately in different formulations.

15. (Currently amended) The method according to claim 13 wherein the ~~13-monosaccharide 5-oxime avermectin, selected from the group consisting of~~ selamectin, and praziquantel are administered in the same formulation.

FORM AMEND
Rev. 5/27/03

PATENT/Docket No. PC22004B
Appl. No. 10/761,636
Filing Date: January 21, 2004
Reply to Office action of July 1, 2005

16. (Currently amended) The method according to claim 13 wherein the ~~13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel~~ are administered via the same route.

17. (Currently amended) A method of treatment according to claim 13 wherein the ~~13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel~~ are administered via different routes.

18. (original) The method according to claim 13 wherein the mammal is a companion animal, selected from the group consisting of a cat.

19. (Currently amended) A kit useful in the treatment of prophylaxis of a parasitic infestation of flea, heartworm or tapeworm in a mammal, which comprises a ~~13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel~~ and a pharmaceutical or veterinary carrier, and instructions for the treatment of a parasitic infestation of flea, heartworm or tapeworm in a mammal, where said instructions include the requirement of a topical application or spot-on application of said selamectin, and praziquantel.

FORM AMEND
Rev. 5/27/03